Mr. Bennett’s recent engagements include:
- Lead counsel for Fresenius Kabi USA, LLC and USV North America as generic defendants in patent litigation concerning the bone disorder treatment Zometa® pending before Judge Susan Davis Wigenton in the U.S. District Court, District of New Jersey.
- Trial Counsel for Fresenius Kabi USA, LLC in patent litigation concerning its branded parenteral anesthetic, Diprivan®, pending before Judge Richard G. Andrews in the U.S. District Court, District of Delaware.
- Trial counsel for Teva Pharmaceuticals in patent litigation concerning its branded treatment for idiopathic Parkinson’s disease, Azilect®. Teva prevailed after a May 2013 bench trial before Judge Claire C. Cecchi in the U.S. District Court, District of New Jersey. Judge Cecchi ruled that Teva’s patent covering Azilect® had been infringed and was not invalid.
- Trial and appellate counsel for Teva Pharmaceuticals in patent litigation concerning its blockbuster innovative treatment for multiple sclerosis, Copaxone®, pending in the U.S. District Court, Southern District of New York. Teva prevailed on all nine patents asserted at the trial court in June 2012 and the Federal Circuit affirmed the judgment in 2013 as to four of the asserted patents.
- Trial and appellate counsel for Teva Pharmaceuticals as a generic defendant in patent litigation concerning Sanofi-Aventis’s blockbuster treatment for deep vein thrombosis, Lovenox®. Teva prevailed after a bench trial in the U.S. District Court, Central District of California before Judge Mariana R. Pfaelzer, resulting in a ruling that Sanofi’s Orange Book patent covering Lovenox® was unenforceable due to inequitable conduct. This ruling was affirmed by the Federal Circuit in 2008.
Mr. Bennett is a member of the Boston and Massachusetts Bar Associations.
Prior to joining Goodwin, Mr. Bennett was an associate with Palmer & Dodge in Boston, where his practice focused on intellectual property matters.